LytM Fusion with SH3b-Like Domain Expands Its Activity to Physiological Conditions

Microb Drug Resist. 2016 Sep;22(6):461-9. doi: 10.1089/mdr.2016.0053. Epub 2016 Jun 28.

Abstract

Staphylococcus aureus remains one of the most common and at the same time the most dangerous bacteria. The spreading antibiotic resistance calls for intensification of research on staphylococcal physiology and development of new strategies for combating this threatening pathogen. We have engineered new chimeric enzymes comprising the enzymatically active domain (EAD) of autolysin LytM from S. aureus and the cell wall binding domain (CBD) from bacteriocin lysostaphin. They display potent activity in extended environmental conditions. Our results exemplify the possibility of exploring autolytic enzymes in engineering lysins with desired features. Moreover, they suggest a possible mechanism of autolysin physiological activity regulation by local ionic environments in the cell wall.

MeSH terms

  • Anti-Bacterial Agents / biosynthesis*
  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism*
  • Bacterial Proteins / pharmacology
  • Cell Wall / chemistry
  • Cell Wall / drug effects
  • Cell Wall / metabolism
  • Endopeptidases / genetics
  • Endopeptidases / metabolism*
  • Endopeptidases / pharmacology
  • Gene Expression
  • Lysostaphin / metabolism*
  • Lysostaphin / pharmacology
  • Microbial Sensitivity Tests
  • Mutation
  • Protein Domains
  • Protein Engineering
  • Recombinant Fusion Proteins / biosynthesis*
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / pharmacology
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / genetics
  • Staphylococcus aureus / metabolism*
  • Structure-Activity Relationship

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Recombinant Fusion Proteins
  • Endopeptidases
  • Lysostaphin
  • LytM protein, Staphylococcus aureus